THE JAN VISHWAS DEBATE
A New Chapter in Healthcare Regulation: Simplifying Compliance or Risking Public Safety?
A major shift is occurring in India’s legal landscape with the introduction of the Jan Vishwas (Amendment of Provisions) Bill, 2026. This landmark legislation seeks to decriminalise minor procedural violations across 79 Central Acts, including key healthcare laws like the Drugs and Cosmetics Act, 1940, and the Clinical Establishments Act, 2010. By replacing imprisonment with civil penalties, the government aims to foster trust-based governance, but the move has sparked a fierce debate over patient safety and institutional accountability.
1. The Government's Vision: Trust-Based Governance
The central theme of the bill is moving away from "excessive criminalisation" for technical lapses. The government frames these reforms as essential for both "Ease of Doing Business" and "Ease of Living".
Replacing Jail with Fines: The bill replaces imprisonment with graded monetary penalties for over 700 provisions across multiple sectors.
Warning Before Punishment: It introduces a tiered enforcement system where first-time or minor lapses are met with advisory notices or warnings rather than immediate fines.
Faster Resolution: New adjudicating officers and appellate authorities will handle these civil penalties, aiming to reduce the massive burden of minor cases in traditional courts.
2. Impact on the Health Sector: Modernising Old Laws
Within the healthcare domain, 35 provisions across five major acts have been amended.
Drugs and Cosmetics Act, 1940: Several minor violations that previously carried jail terms have been substituted with financial penalties. For instance, Section 29, which penalised using a government analyst's report for advertising, has been completely omitted.
Clinical Establishments Act, 2010: The term "fine" has been replaced with "penalty" in key sections to shift enforcement from criminal prosecution to administrative adjudication. This encourages hospitals to take corrective action for deficiencies that don't pose immediate risks to patients, rather than facing criminal trials.
Cosmetics Industry: Manufacturing or selling low-risk cosmetics now falls under an administrative penalty framework if the violations are not related to spurious or adulterated products.
3. The Critical Conflict: Safety vs. Business
While the government sees a more "humane framework," critics view the bill as a dangerous dilution of deterrence.
Dilution of Accountability: Opponents argue that replacing jail time with fines creates a "pay and escape" regime where large corporations can treat penalties as a mere cost of doing business.
Public Health Risks: Critics point out that the bill fails to distinguish clearly between minor procedural errors and serious violations that could endanger lives. Removing imprisonment for substandard drugs or cosmetics is seen by some as a "surrender of the rule of law" for corporate convenience.
Weak Safeguards: Concerns have been raised that the threshold for action and the escalation of penalties are left largely to executive rules without enough judicial checks and balances.
4. The Path Ahead: A Balanced Middle Ground?
The government maintains that serious public safety offences will still attract strict criminal action. The goal is to ensure that honest businesses aren't harassed for simple paperwork errors while maintaining "robust safeguards" for the public. However, the success of the Jan Vishwas Act, 2026, will ultimately depend on how effectively the new adjudicating authorities can balance being "business-friendly" with the sacred duty of protecting patient lives.
🚨 Current Status
The Jan Vishwas (Amendment of Provisions) Bill, 2026, has been passed by both Houses of Parliament. As these reforms are operationalised, the debate continues over whether this "trust-based" system will lead to a more efficient healthcare ecosystem or a "legalized endangerment" of public health.
- Parikshit Sachdeva